| 1 |
32128704 | The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. | 2020 Mar |
1 |
| 2 |
32355687 | Risk management of hepatocellular carcinoma occurrence after hepatitis C virus eradication-from IFN based era to IFN-free DAA era. | 2020 Apr |
1 |
| 3 |
30443787 | Modulation of the Immune System in Chronic Hepatitis C and During Antiviral Interferon-Free Therapy. | 2019 Apr |
1 |
| 4 |
30450781 | Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection. | 2019 Mar |
1 |
| 5 |
30848363 | Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan. | 2019 Aug |
6 |
| 6 |
30941326 | Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. | 2019 |
1 |
| 7 |
31123693 | Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan. | 2019 May |
3 |
| 8 |
31453368 | No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis. | 2019 |
1 |
| 9 |
29205416 | The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. | 2018 Jun |
1 |
| 10 |
29327780 | Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. | 2018 Mar |
3 |
| 11 |
29399282 | Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience. | 2018 Jan 27 |
1 |
| 12 |
29427484 | Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? | 2018 Feb |
1 |
| 13 |
29459562 | [The impact of direct-acting antiviral therapy on the diagnosis of hepatitis-C virus-associated hepatocellular carcinoma]. | 2018 |
1 |
| 14 |
29565742 | An Increase in Expression of SOCS1 Gene with Increase in Hepatitis C Virus Viral Load. | 2018 Mar |
1 |
| 15 |
29577581 | Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients. | 2018 Aug |
1 |
| 16 |
29659591 | Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. | 2018 |
3 |
| 17 |
29704252 | Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy. | 2018 Dec |
2 |
| 18 |
29920131 | Expression of SOCS1 and SOCS3 Genes in Interferon-Treated and Direct-Acting Antiviral Drugs-Treated Hepatitis C Patients. | 2018 Jun |
4 |
| 19 |
30001324 | Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection. | 2018 Jul |
2 |
| 20 |
30026959 | Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis. | 2018 |
2 |
| 21 |
30956892 | Achieving Sustained Viral Remission in Patients with Chronic HCV Infection and Cryoglobulinemic Vasculitis Does Not Always Correlate with Normalization of the Serologic Markers. | 2018 Oct 3 |
1 |
| 22 |
27351356 | Viability of pegIFNα-RBV for CHC in the direct acting antiviral era: a practical algorithm between efficacy and cost containment. | 2017 Apr |
1 |
| 23 |
27685337 | Effect of antiviral therapy for HCV on lipid levels. | 2017 |
2 |
| 24 |
28105744 | Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. | 2017 Apr |
1 |
| 25 |
28195337 | Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. | 2017 Jul |
1 |
| 26 |
28196130 | Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response. | 2017 |
1 |
| 27 |
28249574 | Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature. | 2017 Mar 1 |
2 |
| 28 |
28617830 | On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C. | 2017 |
1 |
| 29 |
28630501 | IFN-λ4 potently blocks IFN-α signalling by ISG15 and USP18 in hepatitis C virus infection. | 2017 Jun 19 |
2 |
| 30 |
28636655 | Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon. | 2017 |
1 |
| 31 |
28857900 | Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience. | 2017 Nov |
1 |
| 32 |
29430221 | Successful Treatment of Oral Lichen Planus with Direct-Acting Antiviral Agents after Liver Transplantation for Hepatitis C Virus-Associated Hepatocellular Carcinoma. | 2017 Sep-Dec |
1 |
| 33 |
26519873 | Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. | 2016 Jan |
2 |
| 34 |
26725891 | Why do I treat my patients with mild hepatitis C? | 2016 Jan |
1 |
| 35 |
26950182 | Comparison of sleep disorders in chronic hepatitis C patients treated with interferon-based therapy and direct acting antivirals using actigraphy. | 2016 Dec |
1 |
| 36 |
25356568 | Chronic hepatitis C: treat everyone now or stratify by disease? | 2015 Mar |
2 |
| 37 |
26482547 | Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals. | 2015 Dec |
1 |
| 38 |
24330005 | Interferon-α/β for treatment of chronic hepatitis C infection in the era of direct-acting antiviral agents. | 2014 Apr |
2 |
| 39 |
24367041 | IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. | 2014 Jun 1 |
1 |
| 40 |
24871445 | Advances in newly developing therapy for chronic hepatitis C virus infection. | 2014 Jun |
1 |
| 41 |
24907428 | Pushing to a cure by harnessing innate immunity against hepatitis C virus. | 2014 Aug |
1 |
| 42 |
24102413 | Emerging treatments for hepatitis C. | 2013 Dec |
1 |
| 43 |
25165553 | An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials. | 2013 Dec |
1 |
| 44 |
21932410 | Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias? | 2012 Jan |
1 |
| 45 |
22300469 | Antiviral strategies in hepatitis C virus infection. | 2012 |
1 |
| 46 |
21897228 | Future of hepatitis C therapy: development of direct-acting antivirals. | 2011 Nov |
2 |